Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 10/20 | 0.49 |
| ▸ | CDK2 | P24941 | 4/20 | 0.49 |
| ▸ | CDK4 | P11802 | 3/20 | 0.49 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.49 |
| ▸ | JAK2 | O60674 | 2/20 | 0.49 |
| ▸ | PLK4 | O00444 | 1/20 | 0.49 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.49 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.49 |
| ▸ | ULK1 | O75385 | 1/20 | 0.49 |
| ▸ | ERN1 | O75460 | 1/20 | 0.49 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | KRAS | P01116 | 1/20 | 0.49 |
| ▸ | RAF1 | P04049 | 1/20 | 0.49 |
| ▸ | LCK | P06239 | 1/20 | 0.49 |
| ▸ | FYN | P06241 | 1/20 | 0.49 |
| ▸ | CDK1 | P06493 | 1/20 | 0.49 |
| ▸ | YES1 | P07947 | 1/20 | 0.49 |
| ▸ | LYN | P07948 | 1/20 | 0.49 |
| ▸ | MET | P08581 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19994675 | 0.91 | BRAF (0.52) | BRAFCDK2CDK4NR1I2JAK2 | |
| SCHEMBL20006053 | 0.86 | BRAF (0.52) | BRAFCDK2CDK4NR1I2JAK2 | |
| SCHEMBL30596126 | 0.86 | BRAF (0.52) | BRAFCDK2CDK4NR1I2JAK2 | |
| SCHEMBL19994708 | 0.86 | BRAF (0.51) | BRAFCDK2CDK4NR1I2JAK2 | |
| SCHEMBL24256996 | 0.84 | BRAF (0.54) | BRAFCDK2CDK4NR1I2JAK2 | |
| SCHEMBL24257065 | 0.83 | BRAF (0.58) | BRAFCDK4NR1I2RIPK2IRAK1 | |
| SCHEMBL30464231 | 0.83 | BRAF (0.58) | BRAFCDK4NR1I2RIPK2IRAK1 | |
| SCHEMBL21312785 | 0.82 | BRAF (0.48) | BRAFCDK2CDK4NR1I2JAK2 | |
| SCHEMBL19994701 | 0.81 | CDK2 (0.51) | BRAFCDK2CDK4NR1I2JAK2 | |
| SCHEMBL19994700 | 0.81 | BRAF (0.75) | BRAFCDK2CDK4NR1I2JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190263796-A1 | LIM KINASE INHIBITORS, PHARMACEUTICAL COMPOSITION AND METHOD OF USE IN LIMK-MEDIATED DISEASES | CELLIPSE (FR) | 2019-08-29 | — | — | US | disclosed |
| WO-2018055097-A1 | LIM KINASE INHIBITORS, PHARMACEUTICAL COMPOSITION AND METHOD OF USE IN LIMK-MEDIATED DISEASES | CELLIPSE (FR) | 2018-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263796-A1 | LIM KINASE INHIBITORS, PHARMACEUTICAL COMPOSITION AND METHOD OF USE IN LIMK-MEDIATED DISEASES | LIMK1, LIMK2, LMTK3 | BRAF 262/4885CDK2 216/4885CDK4 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.